Skip to main content

Elevance Health Inc

For the period ended Mar 31, 2024. Filed Apr 18, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed Apr 18, 2024

ELV$429.65+2.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

UNREGISTERED SALES OF EQUITY SECURITIESAND USE OF PROCEEDS

Issuer Purchases of Equity Securities

The following table presents information related to our repurchases of common stock for the periods indicated:

Period · Total Numberof SharesPurchased1 · AveragePrice Paidper Share · Total Numberof SharesPurchasedas Partof PubliclyAnnouncedPrograms2 · ApproximateDollar Valueof Sharesthat May YetBe PurchasedUnder thePrograms
(in millions, except share and per share data)
January 1, 2024 to January 31, 2024480,285$475.26479,559$3,971
February 1, 2024 to February 29, 2024311,446502.61310,9323,815
March 1, 2024 to March 31, 2024558,218504.76359,0943,633
1,349,9491,149,585

1 Total number of shares purchased includes 200,364 shares delivered to or withheld by us in connection with employee payroll tax withholding upon the exercise or vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated changes in equity are shown net of these shares purchased.

2 Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board of Directors evaluates periodically. During the three months ended March 31, 2024, we repurchased 1,149,585 shares at a total cost of $566 under the program, including the cost of options to purchase shares. The Board of Directors has authorized our common stock repurchase program since 2003. The most recent authorized increase to the program was $5,000 on January 24, 2023 by our Audit Committee, pursuant to authorization granted by the Board of Directors. No duration has been placed on our common stock repurchase program, and we reserve the right to discontinue the program at any time.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.